Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis
Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.
Enterade Partners With 7-Time Olympic Medalist and Cancer Survivor Shannon Miller
UF Innovate startup company Enterade has teamed up with 7-time Olympic medalist, gymnast, and cancer survivor Shannon Miller to promote their non-prescription medical drink as a key part of the chemotherapy healing and recovery process.
Study Provides Preliminary Evidence in Favor of a New Type 1 Diabetes Treatment
Researchers have discovered preliminary evidence for a new type 1 diabetes treatment using the drug DFMO, supplied by UF startup Panbela Therapeutics.
UF Startup RedoxBlox Receives Funding From California Energy Commission as Part of Long-Duration Energy Storage Project
UF startup RedoxBlox recently received $8,936,778 in funding from the California Energy Commission aimed at improving resilience and reliability among low-income and disadvantaged communities.
Atsena Therapeutics Receives FDA Designation for Treatment of Severe Congenital Eye Disease Using Gene Therapy
Atsena Therapeutics has been granted Regenerative Medicine Advanced Therapy designation from the FDA to continue their research on a cure to Leber congenital amaurosis. Patients with this disease are missing a gene that regulates retinal function and visually-guided behavior, causing blindness at an early age.
New Pest Management Hub Will Address Florida’s Buggiest Problems
The University of Florida Institute of Food and Agricultural Sciences (UF/IFAS) will create a new network focused on finding novel ways to manage bugs and pests in homes and businesses, known as the Innovation Hub for Urban Pest Management.
Entrinsic Bioscience Announces Breakthrough Innovation for Next Generation Sports and Recreational Rehydration™ Beverages
Entrinsic Bioscience has published a ground-breaking clinical study demonstrating the potential for next-generation sports and rehydration beverages, powered by its new Ultra-Hydrating HeatDefense™ formula which promotes dual action rapid rehydration with new levels of heat protection during sports, physical exertion and high heat stress.
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy using technology discovered at the University of Florida, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated.
“The Horse’s Mouth” with Enrico Levi of Inzecto
The Horse’s Mouth is a talk show where Tom McManus’s guests sidle up to his bar to discuss the intersection of sports, business, and life. Today, Tom sits with Enrico Levi of Inzecto, a UF startup licensing mosquito control technology created by Levi, Roberto Pereira, and principal investigator Philip Koehler at the UF College of Agriculture and Food Sciences.
BioMérieux Receives CE Mark for Biomarker Assay for Mild TBI
BioMérieux, which signed an agreement in 2017 with Banyan Biomarkers to commercialize its TBI assay, has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
